Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
BACKGROUND Patients on regular hemodialysis present high cardiovascular mortality . Uremic dyslipidemia and inflammation take part in the etiology of atherosclerosis . Rosuvastatin calcium has not been studied in patients on dialysis to date . We sought to evaluate the results of rosuvastatin therapy regarding lipids , lipoproteins and a marker of inflammation in hemodialysis patients . METHODS In a double-blind r and omized placebo-controlled trial , 59 patients on hemodialysis ( 31 in the placebo group , and 28 taking rosuvastatin 10 mg/day ) were followed for 3 months . Lipids , lipoproteins and high-sensitivity C-reactive protein ( hs-CRP ) were measured at baseline , 30 days and 3 months . RESULTS In the rosuvastatin group , there was a significant decrease from baseline to the study end in total cholesterol ( 163+/-53 mg/dL to 142+/-43 mg/dL ; p<0.05 ) , in LDL cholesterol ( 90+/-39 mg/dL to 69+/-32 mg/dL ; p<0.05 ) and in non-HDL cholesterol ( 121+/-46 mg/dL to 99+/-39 mg/dL ; p<0.05 ) . In the placebo group , no significant decrease was observed . High-sensitivity CRP was lower in the rosuvastatin than in the placebo group at 3 months ( p<0.01 ) . CONCLUSIONS Rosuvastatin calcium at 10 mg/day was effective in lowering total cholesterol , LDL cholesterol , non-HDL cholesterol and hs-CRP in hemodialysis patients
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .